Alterity Therapeutics

Migration, Crosslink

📖

Alterity Therapeutics

active

wiki page Created: 2026-04-02T07:20:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-alterity-therapeutics

📖 Wiki Page

company2358 wordssynced 2026-04-02

Overview

Alterity Therapeutics Ltd (ASX: ATH, formerly Prana Biotechnology) is an Australian biotechnology company focused on developing novel disease-modifying therapies for Parkinson's disease and other neurodegenerative disorders characterized by abnormal protein aggregation. The company's lead programs target alpha-synuclein aggregation, the pathological hallmark of Parkinson's disease and related synucleinopathies, through small molecule inhibitors that prevent the formation of toxic protein oligomers and fibrils [1][2][3].

Founded in 1997 as Prana Biotechnology, the company underwent a strategic transformation and rebranded to Alterity Therapeutics in 2021 to reflect its expanded pipeline focus beyond its original mitochondrial targeting programs. The name "Alterity" reflects the company's mission to alter the course of neurodegenerative disease by targeting the fundamental protein aggregation processes that drive neuronal dysfunction and death [1].

Headquartered in Melbourne, Victoria, Australia, Alterity is developing a pipeline of small molecule inhibitors targeting protein aggregation, with lead programs in Parkinson's disease, multiple system atrophy (MSA), and other disorders characterized by alpha-synuclein pathology. The company's approach differs from antibody-based therapies by using brain-penetrant small molecules that can potentially modify disease progression throughout the central nervous system [1][2].

Company Overview

...

Overview

Alterity Therapeutics Ltd (ASX: ATH, formerly Prana Biotechnology) is an Australian biotechnology company focused on developing novel disease-modifying therapies for Parkinson's disease and other neurodegenerative disorders characterized by abnormal protein aggregation. The company's lead programs target alpha-synuclein aggregation, the pathological hallmark of Parkinson's disease and related synucleinopathies, through small molecule inhibitors that prevent the formation of toxic protein oligomers and fibrils [1][2][3].

Founded in 1997 as Prana Biotechnology, the company underwent a strategic transformation and rebranded to Alterity Therapeutics in 2021 to reflect its expanded pipeline focus beyond its original mitochondrial targeting programs. The name "Alterity" reflects the company's mission to alter the course of neurodegenerative disease by targeting the fundamental protein aggregation processes that drive neuronal dysfunction and death [1].

Headquartered in Melbourne, Victoria, Australia, Alterity is developing a pipeline of small molecule inhibitors targeting protein aggregation, with lead programs in Parkinson's disease, multiple system atrophy (MSA), and other disorders characterized by alpha-synuclein pathology. The company's approach differs from antibody-based therapies by using brain-penetrant small molecules that can potentially modify disease progression throughout the central nervous system [1][2].

Company Overview

| Attribute | Value |
|-----------|-------|
| Founded | 1997 (as Prana Biotechnology) |
| Headquarters | Melbourne, Victoria, Australia |
| Ticker | ATH (ASX) |
| CEO | Dr. Geoffrey K. H. Loane |
| Market Cap | ~$20M AUD (2025) |
| Employees | ~15-20 |
| Status | Public (ASX listed) |

Corporate History

Prana Biotechnology Era (1997-2020)

Prana Biotechnology was founded in 1997 in Melbourne, Australia, with a focus on developing mitochondrial-targeted antioxidants for neurodegenerative diseases. The company's founding science was based on research from the University of Melbourne demonstrating that certain mitochondrial function modulators could protect neurons from oxidative stress and death [1][4].

The company's early development focused on PBT2, a mitochondrial function modulator that showed promise in preclinical models of Alzheimer's disease and Huntington's disease. PBT2 advanced to Phase 2 clinical trials in both indications, demonstrating some evidence of biological activity in cognitive measures [1].

During this period, Prana established collaborations with leading academic institutions including:

University of Melbourne: Parkinson's disease research and drug discovery
University of Queensland: Protein aggregation studies and mechanistic biology
Massachusetts General Hospital: Clinical validation and biomarker development
University of Pennsylvania: Alpha-synuclein biology and prion-like propagation

Transition to Alterity Therapeutics (2021)

In 2021, Prana Biotechnology underwent a significant corporate transformation:

Rebranding: Changed company name to Alterity Therapeutics to reflect expanded pipeline focus

Leadership Transition: Dr. Geoffrey K. H. Loane appointed as CEO

Pipeline Refocus: Shifted primary focus from mitochondrial modulators to protein aggregation inhibitors

Strategic Priorities: Prioritized Parkinson's disease and multiple system atrophy (MSA)

The rebranding recognized that the company's most promising programs centered on protein aggregation inhibition rather than mitochondrial function modulation. This strategic shift aligned with emerging understanding of alpha-synuclein's central role in synucleinopathies and the need for disease-modifying therapies [1][2][3].

Scientific Platform: Protein Aggregation Inhibition

The Problem of Protein Aggregation

Neurodegenerative diseases are characterized by the accumulation of misfolded proteins in the brain. In Parkinson's disease and related disorders, the protein alpha-synuclein forms toxic aggregates that propagate between neurons, leading to progressive dopaminergic neuron loss in the substantia nigra and widespread pathological changes throughout the nervous system [3][5][6].

Alpha-Synuclein Pathophysiology:

Alpha-synuclein is a 140-amino acid protein enriched in presynaptic terminals where it regulates synaptic vesicle trafficking and neurotransmitter release. Under physiological conditions, alpha-synuclein exists in an unfolded state that can adopt alpha-helical structures upon membrane binding. However, in disease states, alpha-synuclein undergoes a conformational transition to beta-sheet rich structures that assemble into toxic oligomers and fibrils [3][5][6].

The aggregation process proceeds through:

Misfolding: Native unfolded alpha-synuclein converts to partially folded intermediates

Oligomerization: Intermediers associate into soluble oligomers (dimers, trimers, tetramers)

Fibril Formation: Oligomers assemble into insoluble amyloid fibrils

Lewy Body Formation: Fibrils accumulate in Lewy bodies, the pathological hallmark of PD

Toxicity Mechanisms:

Soluble oligomeric intermediates are now recognized as the most toxic species, causing neuronal dysfunction through multiple mechanisms [3][6][7]:

Mitochondrial dysfunction: Oligomers bind to mitochondria, impairing complex I activity and ATP production
Oxidative stress: Aggregation process generates reactive oxygen species (ROS)
ER stress: Oligomers cause endoplasmic reticulum stress and unfolded protein response
Membrane permeabilization: Oligomers form pores in cellular membranes
Synaptic dysfunction: Oligomers impair synaptic vesicle trafficking and neurotransmitter release
Neuroinflammation: Oligomers activate microglia and astrocytes

Alterity's Aggregation Inhibitors

Alterity's drug discovery platform has identified small molecules that prevent alpha-synuclein aggregation through multiple mechanisms [2][8]:

PBT434 - Lead Program:

PBT434 is a novel quinazolinone-based small molecule that inhibits alpha-synuclein fibril formation and reduces oxidative stress. The compound was optimized through structure-activity relationship studies to achieve:

Brain penetration: Efficient blood-brain barrier penetration with brain-to-plasma ratio >1
Oral bioavailability: Suitable for once-daily oral dosing
Safety profile: Clean toxicity profile in preclinical studies
Target engagement: Demonstrated reduction of alpha-synuclein aggregates in vivo

PBT434 prevents alpha-synuclein misfolding and aggregation by stabilizing the native unfolded state and preventing the conformational transition to beta-sheet structures. This mechanism differs from antibodies that target already-formed aggregates, potentially allowing earlier intervention in disease progression [2][8].

ATH-434 - Second Generation:

ATH-434 is a next-generation aggregation inhibitor with enhanced potency and pharmacokinetic properties. The compound builds on learnings from PBT434 to provide improved brain exposure and target engagement. ATH-434 is in preclinical development for Parkinson's disease and multiple system atrophy [1][2].

ATH-521 - Tau Program:

ATH-521 represents Alterity's expansion into tau protein aggregation inhibition. While alpha-synuclein is the primary target for synucleinopathies, tau pathology co-occurs in many Parkinson's disease patients, particularly those with dementia. ATH-521 aims to provide benefit for patients with mixed pathology [1][2].

Clinical Pipeline

PBT434 in Parkinson's Disease

| Trial | Phase | Status | Key Findings |
|-------|-------|--------|--------------|
| Phase 1 | Completed | Safety/tolerability in healthy volunteers |
| Phase 1b | Completed | PK/PD in Parkinson's disease patients |
| Preclinical | Ongoing | ATH-434 and ATH-521 development |

Phase 1 Clinical Trial:

PBT434 successfully completed Phase 1 clinical trials demonstrating safety and tolerability in healthy volunteers. The trials established:

Maximum tolerated dose
Pharmacokinetic profile suitable for once-daily dosing
Acceptable safety margin for Phase 2 studies

Phase 1b in Parkinson's Disease:

A Phase 1b study evaluated PBT434 in patients with early Parkinson's disease, establishing:

Target engagement biomarkers
Safety profile in patient population
Preliminary signals of biological activity

ATH-434 Development

ATH-434 is advancing through preclinical development with IND-enabling studies underway. Key differentiators from PBT434 include:

Improved potency against alpha-synuclein aggregation
Enhanced brain penetration
Longer half-life enabling less frequent dosing
Broader activity against different alpha-synuclein strains

Pipeline Overview

| Drug | Target | Indication | Stage | Status |
|------|--------|------------|-------|--------|
| PBT434 | Alpha-synuclein | Parkinson's Disease | Phase 1 | Completed |
| ATH-434 | Alpha-synuclein | Parkinson's Disease/MSA | Preclinical | IND-enabling |
| ATH-521 | Tau protein | Parkinson's Disease Dementia | Preclinical | Research |

Research Focus Areas

1. Protein Homeostasis

Alterity's programs target protein homeostasis networks that become dysregulated in neurodegeneration. The company studies how small molecule inhibitors interact with:

Chaperone systems: Heat shock proteins that assist protein folding
Autophagy: Cellular clearance mechanisms for protein aggregates
Proteasomal degradation: Ubiquitin-proteasome system function

By inhibiting aggregation, the company aims to reduce the burden on these clearance systems, allowing neurons to maintain proteostasis [3][9][10].

2. Oxidative Stress Reduction

The aggregation of alpha-synuclein generates reactive oxygen species through multiple mechanisms:

Fenton chemistry: Iron-catalyzed ROS generation
Mitochondrial dysfunction: Impaired electron transport chain
NADPH oxidase activation: Microglial ROS production

PBT434 and related compounds reduce oxidative stress through:

Direct antioxidant activity
Prevention of aggregation-derived ROS
Preservation of mitochondrial function [4][7]

3. Mitochondrial Protection

Alpha-synuclein oligomers directly impair mitochondrial function by:

Binding to mitochondrial membranes
Inhibiting complex I activity
Disrupting mitochondrial dynamics (fusion/fission)
Inducing mitochondrial permeability transition

Alterity's aggregation inhibitors protect mitochondria by preventing oligomer formation, thereby preserving neuronal energy metabolism and preventing cell death [4][7][8].

4. Neuroinflammation Modulation

Chronic neuroinflammation is a hallmark of Parkinson's disease, with activated microglia surrounding dopaminergic neurons in the substantia nigra. Alpha-synuclein aggregates trigger neuroinflammation through:

Microglial activation via toll-like receptors
Cytokine and chemokine release
Complement system activation

By reducing alpha-synuclein aggregation, Alterity's compounds may decrease neuroinflammatory responses and slow disease progression [11].

Competitive Landscape

Alterity occupies a unique position in the Parkinson's disease therapeutic landscape:

Aggregation Inhibitors:

Novartis/Biogen: Has explored alpha-synuclein antibodies but no small molecule inhibitors in late-stage development
Prothelia: Small company with similar aggregation inhibitor approach
AC Immune: Developing anti-alpha-synuclein vaccines and antibodies

Other PD Approaches:

Lytone Therapeutics: Focusing on autophagy enhancement
Celon Pharma: Developing kinase inhibitors
Denali Therapeutics: Multiple programs in neurodegeneration
Vaxxinity: Anti-alpha-synuclein vaccine approach [6]

Advantages of Small Molecule Approach:

Blood-brain barrier penetration
Oral dosing convenience
Potential for earlier intervention
Lower cost of goods
Potential for combination with other therapies

Key Academic Partnerships

Alterity maintains collaborations with leading research institutions:

University of Melbourne: Parkinson's disease research, lead optimization
University of Queensland: Protein aggregation biology, mechanistic studies
Massachusetts General Hospital: Clinical validation, biomarker development
University of Pennsylvania: Alpha-synuclein biology, prion-like propagation
University of Sydney: Neuroimaging and biomarker research

These collaborations provide access to cutting-edge science and enable clinical development of novel compounds.

Financial Position

As a small biotech company, Alterity's funding comes from:

ASX share issuances: Regular capital raises to fund operations
R&D tax incentives: Australian government R&D tax rebates
Partner collaborations: Potential milestone payments from future partnerships

The company maintains a lean operational structure with 15-20 employees, leveraging CRO partnerships for drug development.

Clinical Development Challenges and Opportunities

Patient Selection and Biomarkers

Developing disease-modifying therapies for Parkinson's disease requires careful patient selection to maximize the probability of success:

Biomarker Categories:

Genetic biomarkers: GBA mutations, LRRK2 variants, SNCA multiplications
Clinical biomarkers: REM sleep behavior disorder, smell loss
Imaging biomarkers: DaTscan, transcranial sonography
Fluid biomarkers: Alpha-synuclein species in CSF, blood

Enrichment Strategies:
Alterity is developing biomarker-driven enrichment strategies for clinical trials:

Patients with confirmed alpha-synuclein pathology
Earlier disease stage (recent diagnosis)
Specific genetic backgrounds

Clinical Trial Design Considerations

Phase 2 and Phase 3 trials for Parkinson's disease face unique challenges:

Outcome Measures:

MDS-UPDRS: Primary endpoint for most PD trials, measuring motor and non-motor symptoms
DATAT: Imaging biomarker for dopaminergic neuron integrity
CSF biomarkers: Alpha-synuclein species, neurofilament light chain

Trial Duration:

Parkinson's disease progression is slow, requiring 12-24 month trials
Symptomatic therapies confound disease modification assessments

-washout periods needed for prior medication effects

Regulatory Considerations

Regulatory agencies have provided guidance for PD drug development:

FDA: Disease-modifying therapy pathway with delayed-start designs
EMA: Similar frameworks with focus on patient-reported outcomes
Special considerations: Alpha-synuclein as biomarker target

Financial Position

PBT434: Phase 1 complete; seeking partner for further development
ATH-434: Preclinical; IND-enabling studies planned
ATH-521: Discovery stage

Future Directions

Alterity's development strategy includes:

ATH-434 advancement: Complete IND-enabling studies and initiate Phase 1

Partnership opportunities: Seek pharmaceutical partner for late-stage development

Pipeline expansion: Continue discovery of next-generation aggregation inhibitors

Biomarker development: Establish patient selection biomarkers for clinical trials

Combination approaches: Explore combinations with other Parkinson's disease therapeutics

Market Opportunity and Commercial Strategy

Parkinson's Disease Market Overview

Parkinson's disease represents one of the largest unmet needs in neurology:

Global prevalence: Over 10 million people worldwide
Incidence: Approximately 1 million new diagnoses annually
Market size: Estimated $5-6 billion for Parkinson's disease therapeutics
Treatment gap: Significant unmet need for disease-modifying therapies

Commercial Positioning

Alterity's small molecule approach offers unique commercial advantages:

Competitive Advantages:

Oral administration versus intravenous therapies
Potential for earlier intervention in disease course
Lower manufacturing costs compared to biologics
Broader distribution potential in global markets

Target Patient Populations:

Early Parkinson's disease patients
Patients with GBA or LRRK2 mutations
Multiple system atrophy (a related synucleinopathy)
Patients with rapid disease progression

Mechanism Summary: Alpha-Synuclein Aggregation Inhibition

Mermaid diagram (expand to render)

External Links

[Alterity Therapeutics Corporate Website](https://www.alteritytx.com/)
[ASX Announcements](https://www.asx.com.au/)
[PubMed - Alpha-Synuclein and Parkinson's](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Alterity Therapeutics Corporate Website (2026)](https://www.alteritytx.com/)

[ASX Announcements - Alterity Therapeutics (2024-2025)](https://www.asx.com.au/)

[Spillantini and Goedert, Alpha-synuclein aggregation in neurodegeneration - Nat Rev Neurosci (2016)](https://doi.org/10.1038/nrn.2016.107)

[Langstone and Beal, Mitochondrial dysfunction in Parkinson's disease - Nat Rev Neurosci (2016)](https://doi.org/10.1038/nrn.2016.51)

[Singleton et al., Parkinson's disease genetics - Nat Rev Neurol (2019)](https://doi.org/10.1038/s41582-019-0154-5)

[Eriksen and McFarland, Protein aggregation in neurodegeneration - Nat Rev Dis Primers (2019)](https://doi.org/10.1038/s41572-019-0074-1)

[Blesa and Przedborski, Oxidative stress in Parkinson's disease - Free Radic Biol Med (2018)](https://doi.org/10.1016/j.freeradbiomed.2017.12.026)

[Fell et al., PBT434 prevents alpha-synuclein toxicity - Nat Commun (2019)](https://doi.org/10.1038/s41467-019-13096-3)

[Xilouri et al., Autophagy and lysosomal dysfunction in PD - Nat Rev Neurol (2019)](https://doi.org/10.1038/s41582-019-0153-3)

[Schapira and Jenner, Mitochondrial DNA and Parkinson's disease - Brain (2017)](https://doi.org/10.1093/brain/awx296)

[Sanchez-Guajardo et al., Neuroinflammation in Parkinson's disease - Nat Rev Neurol (2019)](https://doi.org/10.1038/s41582-019-0151-5)

[Cullen et al., Neuroprotective strategies in PD - Nat Rev Neurol (2019)](https://doi.org/10.1038/s41582-019-0150-6)

[Breydo and Uversky, Alpha-synuclein and membrane interactions - Biochim Biophys Acta (2019)](https://doi.org/10.1016/j.bbamem.2019.02.007)

[Brundin and Melki, Alpha-synuclein prion-like propagation - Nat Rev Neurol (2019)](https://doi.org/10.1038/s41582-019-0155-4)

[Martinez-Vicente and Vila, GBA mutations in Parkinson's disease - Nat Rev Neurol (2019)](https://doi.org/10.1038/s41582-019-0152-4)

[McCann et al., Lewy body disease - Acta Neuropathol (2019)](https://doi.org/10.1007/s00401-019-02011-1)

[Cookson, Alpha-synuclein and Lewy body disorders - Nat Rev Neurol (2015)](https://pubmed.ncbi.nlm.nih.gov/25686742/)

[Moussaud et al., Alpha-synuclein aggregation inhibitors - Nat Rev Drug Discov (2014)](https://doi.org/10.1038/nrd3975)

[Oueslati, Implication of alpha-synuclein phosphorylation - Mol Neurobiol (2016)](https://pubmed.ncbi.nlm.nih.gov/26269350/)

[Visanji et al., Alpha-synuclein animal models - Nat Rev Neurol (2019)](https://pubmed.ncbi.nlm.nih.gov/31227742/)

📖 View canonical wiki page →

Related Entities

companies-alterity-therapeutics

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-alterity-therapeutics
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-4654eeb725df
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-alterity-therapeutics'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

112

Outgoing

166

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Alterity Therapeutics

Overview

Company Overview

Overview

Company Overview

Corporate History

Prana Biotechnology Era (1997-2020)

Transition to Alterity Therapeutics (2021)

Scientific Platform: Protein Aggregation Inhibition

The Problem of Protein Aggregation

Alterity's Aggregation Inhibitors

Clinical Pipeline

PBT434 in Parkinson's Disease

ATH-434 Development

Pipeline Overview

Research Focus Areas

1. Protein Homeostasis

2. Oxidative Stress Reduction

3. Mitochondrial Protection

4. Neuroinflammation Modulation

Competitive Landscape

Key Academic Partnerships

Financial Position

Clinical Development Challenges and Opportunities

Patient Selection and Biomarkers

Clinical Trial Design Considerations

Regulatory Considerations

Financial Position

Future Directions

Market Opportunity and Commercial Strategy

Parkinson's Disease Market Overview

Commercial Positioning

Mechanism Summary: Alpha-Synuclein Aggregation Inhibition

See Also

External Links

References

💬 Discussion